{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:01:27Z","timestamp":1780542087928,"version":"3.54.1"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MPs"],"abstract":"<jats:p>The effect of administration routes (oral and rectal) on the pharmacokinetics of Salmonella phage SE40 and Escherichia phage V18 was studied. To detect phages in biomaterial (blood, urine, and feces), the Spot-test, Gratia, and double-nested polymerase chain reaction methods were used. Systemic action of the studied phages with both routes of administration, beginning 15\u201330 min after administration, was demonstrated. The phages persisted for up to 24 h after both oral and rectal administration. However, the concentration in the blood was higher after oral administration, while concentrations in urine and feces were higher after rectal administration. The need to protect phages from the acidic contents of the stomach was confirmed.<\/jats:p>","DOI":"10.3390\/mps9030089","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:08:02Z","timestamp":1780535282000},"page":"89","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Study of Bacteriophage Pharmacokinetics by Different Enteral Administration Routes"],"prefix":"10.3390","volume":"9","author":[{"given":"Maria","family":"Anurova","sequence":"first","affiliation":[{"name":"Sechenov First Moscow State Medical University, 8-2 Trubetskaya Street, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0711-6310","authenticated-orcid":false,"given":"Aleksey","family":"Kuzmin","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, 8-2 Trubetskaya Street, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-2464","authenticated-orcid":false,"given":"Aleksey","family":"Vorobev","sequence":"additional","affiliation":[{"name":"Federal Budgetary Institution of Science \u00abMoscow Research Institute of Epidemiology and Microbiology named after G. N. Gabrichevsky\u00bb, Federal Service for Surveillance on Consumer Protection and Human Health (Rospotrebnadzor), 10 Admirala Makarova Street, Moscow 125212, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-2788","authenticated-orcid":false,"given":"Nataliya","family":"Feldman","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, 8-2 Trubetskaya Street, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zinurova","sequence":"additional","affiliation":[{"name":"Sechenov First Moscow State Medical University, 8-2 Trubetskaya Street, Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Aleshkin","sequence":"additional","affiliation":[{"name":"Orphan-Bio LLC, Triumphalny Proezd, 1, Sirius 354340, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","first-page":"e00012","article-title":"Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies","volume":"83","author":"Abedon","year":"2019","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","article-title":"Formulation, stabilization and encapsulation of bacteriophage for phage therapy","volume":"249","author":"Malik","year":"2017","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s00253-018-8811-1","article-title":"Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: An ambitious and also a realistic application?","volume":"102","author":"Maciejewska","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1067\/mcp.2000.109520","article-title":"Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals","volume":"68","author":"Payne","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1099\/mic.0.27849-0","article-title":"Phage therapy: The Escherichia coli experience","volume":"151","year":"2005","journal-title":"Microbiology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/bact.1.2.15845","article-title":"Phage treatment of human infections","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1128\/AEM.01257-12","article-title":"Significance of the bacteriophage treatment schedule in reducing Salmonella colonization of poultry","volume":"78","author":"Bardina","year":"2012","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"41441","DOI":"10.1038\/srep41441","article-title":"Microencapsulation with alginate\/CaCO3: A strategy for improved phage therapy","volume":"7","author":"Colom","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e01870-19","DOI":"10.1128\/AAC.01870-19","article-title":"Efficacy of Bacteriophages in a Staphylococcus aureus Nondiabetic or Diabetic Foot Infection Murine Model","volume":"64","author":"Albac","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","first-page":"110","article-title":"Could bacteriophages isolated from the sewage be the solution to methicillin-resistant Staphylococcus aureus?","volume":"75","author":"Tan","year":"2020","journal-title":"Med. J. Malays."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.medmal.2020.02.004","article-title":"Combining bacteriophages and dalbavancin for salvage therapy of complex Staphylococcus aureus extradural empyema","volume":"50","author":"Bleibtreu","year":"2020","journal-title":"Med. Mal. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1574884715666200330105411","article-title":"Experimental phage therapies in companion animals with historical review","volume":"16","author":"Pyzik","year":"2021","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.22159\/ijcpr.2023v15i5.3056","article-title":"\u2018Bacteriophage therapy\u2019 an emerging cure for bacterial disease","volume":"15","author":"Gupta","year":"2023","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"ref_14","first-page":"384","article-title":"Distribution, isolation and characterization of lytic bacteriophages against multi-drug resistant and extended-spectrum of \u00ee2-lactamase producing pathogens from hospital effluents","volume":"8","author":"Duraisamy","year":"2015","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/AAC.49.7.2874-2878.2005","article-title":"Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy","volume":"49","author":"Bruttin","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.virol.2012.09.002","article-title":"Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh","volume":"434","author":"Sarker","year":"2012","journal-title":"Virology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/1462-2920.13574","article-title":"Oral application of Escherichia coli bacteriophage: Safety tests in healthy and diarrheal children from Bangladesh","volume":"19","author":"Sarker","year":"2017","journal-title":"Environ. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Leitner, L., Sybesma, W., Chanishvili, N., Goderdzishvili, M., Chkhotua, A., Ujmajuridze, A., Schneider, M.P., Sartori, A., Mehnert, U., and Bachmann, L.M. (2017). Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomized, placebo-controlled, double-blind clinical trial. BMC Urol., 17.","DOI":"10.1186\/s12894-017-0283-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Lin","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e0004424","DOI":"10.1128\/cmr.00044-24","article-title":"Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A review with a focus on multidrug-resistant Gram-negative bacterial infections","volume":"37","author":"Siopi","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","article-title":"Pharmacokinetics\/pharmacodynamics of phage therapy: A major hurdle to clinical translation","volume":"29","author":"Nang","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121206","DOI":"10.1016\/j.ijpharm.2021.121206","article-title":"Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections","volume":"609","author":"Khanal","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.resmic.2018.05.011","article-title":"High precision microfluidic microencapsulation of bacteriophages for enteric delivery","volume":"169","author":"Vinner","year":"2018","journal-title":"Res. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Dhungana, G., Nepal, R., Regmi, M., and Malla, R. (2021). Pharmacokinetics and Pharmacodynamics of a Novel Virulent Klebsiella Phage Kp_Pokalde_002 in a Mouse Model. Front. Cell Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.684704"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2300355","DOI":"10.1002\/adtp.202300355","article-title":"Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy","volume":"7","author":"Kang","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_26","first-page":"563","article-title":"Studies on bacteriophage penetration in patients subjected to phage therapy","volume":"35","author":"Dabrowski","year":"1987","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vetmic.2008.10.021","article-title":"Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs","volume":"136","author":"Jamalludeen","year":"2009","journal-title":"Vet. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e0150625","DOI":"10.1128\/aac.01506-25","article-title":"Whole-body distribution of three Pseudomonas phages characterized by a translational physiologically based pharmacokinetic model","volume":"70","author":"Echterhof","year":"2026","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12275-011-1512-4","article-title":"Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models","volume":"49","author":"Tiwari","year":"2011","journal-title":"J. Microbiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/med.21572","article-title":"Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review","volume":"39","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1128\/AAC.48.7.2558-2569.2004","article-title":"In vitro and in vivo bacteriolytic activities of Escherichia coli phages: Implications for phage therapy","volume":"48","author":"Sidoti","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"128013","DOI":"10.1016\/j.micres.2024.128013","article-title":"Salmonella: Infection mechanism and control strategies","volume":"292","author":"Lu","year":"2025","journal-title":"Microbiol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, X., Li, J., Ge, Z., Fan, J., Ma, D., Cao, H., Shen, J., Wang, Y., Liu, Z., and Gomaa, S.E. (2025). Phage therapy for intestinal infections: Efficacy, challenges, and future directions in translational research. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1672198"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e0013621","DOI":"10.1128\/CMR.00136-21","article-title":"Intestinal Bacteriophage Therapy: Looking for Optimal Efficacy","volume":"34","author":"Javaudin","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ebiom.2015.12.023","article-title":"Oral Phage Therapy of Acute Bacterial Diarrhea with Two Coliphage Preparations: A Randomized Trial in Children from Bangladesh","volume":"4","author":"Sarker","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","article-title":"Clinical aspects of phage therapy","volume":"83","author":"Borysowski","year":"2012","journal-title":"Adv. Virus Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clin. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13099-025-00735-y","article-title":"Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections","volume":"17","author":"Youssef","year":"2025","journal-title":"Gut Pathog."}],"container-title":["Methods and Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-9279\/9\/3\/89\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:11:43Z","timestamp":1780539103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-9279\/9\/3\/89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["mps9030089"],"URL":"https:\/\/doi.org\/10.3390\/mps9030089","relation":{},"ISSN":["2409-9279"],"issn-type":[{"value":"2409-9279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}